Results 71 to 80 of about 2,458 (200)

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity [PDF]

, 2021
Inhibidors de la via PI3K; Mecanismes de resistènciaInhibidores de la vía PI3K; Mecanismos de resistenciaPI3K pathway inhibitors; mechanisms of resistanceThe phosphatidylinositol-3-kinase (PI3K) pathway plays a central role in the regulation of several ...
Eichhorn, Pieter Johan Adam, Rodon Ahnert, Jordi, Serra Elizalde, Violeta, Vasilevski, Natali, Wright, Sarah Christine Elisabeth   +4 more
core   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, Volume 599, Issue 20, Page 2896-2910, October 2025.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome

Frontiers in Medicine, 2019
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin.
Tomonori Oka, Tomomitsu Miyagaki
doaj   +1 more source

Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models [PDF]

, 2022
Numerous targeted therapies have been developed for diffuse large B-cell lymphoma, but the results of late-stage clinical trials were mostly disappointing and have led to very few new regulatory approvals.
Bertram, Katrin, Boudesco, Christophe, Dalal, Vineet, Fullin, Jonas, Leary, Peter John, Müller, Anne, Stirm, Kristin, Tzankov, Alexandar, Zenz, Thorsten   +8 more
core   +1 more source

Relapsed Chronic Lymphocytic Leukemia Heralded by Parathyroid Hormone Related Peptide‐Mediated Hypercalcemia

Clinical Case Reports, Volume 13, Issue 10, October 2025.
Recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presenting with severe parathyroid hormone related peptide‐mediated hypercalcemia. Bone marrow and paravertebral biopsies confirmed relapse without evidence of Richter's transformation.
Srikar Tallavajhala, Joanna Lee, Sean C. Dougherty, Brett R. Kurpiel, Craig A. Portell   +4 more
wiley   +1 more source

Anti‐SARS‐CoV‐2 Spike IgA2 Induces Inflammation by Human Macrophages

European Journal of Immunology, Volume 55, Issue 10, October 2025.
Anti‐SARS‐CoV‐2 spike IgA drives inflammation in human macrophages through FcαRI‐Syk signaling. IgA2 immune complexes amplify cytokine production and alter glycolysis and mitochondrial function more potently than IgA1, indicating subclass‐specific immunometabolic reprogramming.
Lynn Mes, Jennifer Veth, Julie Van Coillie, Jim B. D. Keijser, Elise Mantel, Richard van der Mast, Theo Rispens, Gestur Vidarsson, Marjolein van Egmond, Jeroen den Dunnen, Hung‐Jen Chen   +10 more
wiley   +1 more source

Loss of PI3Kδ Activity Drives Autoimmune Colitis by Impairing Extrathymic Treg Differentiation

European Journal of Immunology, Volume 55, Issue 10, October 2025.
Mice with inactivated PI3Kδ develop colitis, reminiscent of immune‐related adverse effects observed in human patients treated with PI3Kδ inhibitors. We demonstrate that loss of PI3Kδ activity abrogates the Helios− peripherally induced Treg (pTreg) population in the mouse colon, resulting in inflammation and tissue damage that Helios+ thymic Tregs fail ...
Ee Lyn Lim, Yamin Qian, Fuminori Sugihara, Atsushi Tanaka, Shimon Sakaguchi   +4 more
wiley   +1 more source

High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions

Cell Reports, 2019
Summary: Deregulated signal transduction is a cancer hallmark, and its complexity and interconnectivity imply that combination therapy should be considered, but large data volumes that cover the complexity are required in user-friendly ways.
Marsilius Mues, Laila Karra, Damia Romero-Moya, Anica Wandler, Matthew J. Hangauer, Olga Ksionda, Yvonne Thus, Marthe Lindenbergh, Kevin Shannon, Michael T. McManus, Jeroen P. Roose   +10 more
doaj   +1 more source

Development and Comparative Evaluation of Two Different Label-Free and Sensitive Fluorescence Platforms for Analysis of Olaparib: A Recently FDA-Approved Drug for the Treatment of Ovarian and Breast Cancer

Molecules, 2023
Olaparib (OLA) is a PARP inhibitor drug which has been recently approved by the Food and Drug Administration (FDA) for the treatment of ovarian and breast cancer.
Ibrahim A. Darwish, Nasr Y. Khalil
doaj   +1 more source

PI3Kγ in Tumour Inflammation: Bridging Immune Response and Cancer Progression—A Mini‐Review

Immunology, Volume 176, Issue 2, Page 215-223, October 2025.
Myeloid cell PI3Kγ can be activated by G Protein‐Coupled Receptors or Receptor Tyrosine Kinases. Once activated, PI3Kγ promotes integrin activation as well as Akt and mTOR activation, thereby promoting transcription of immune‐suppressive and pro‐angiogenic factors, such as Arginase, IL‐10, TGFβ and VEGF‐A.
Anghesom Ghebremedhin, Judith A. Varner
wiley   +1 more source